Peptides for radionuclide therapy

Targeted Radionuclide Tumor Therapy: Biological Aspects

Volumn , Issue , 2008, Pages 117-144

  De Jong, Marion ^a   Verwijnen, Suzanne M ^a   De Visser, Monique ^a   Kwekkeboom, Dik J ^a   Valkema, Roelf ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77952241320     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8696-0_7     Document Type: Chapter

References (172)

1. Krenning, E. P., Teunissen, J. J., Valkema, R., et al.: Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors. J Endocrinol Invest 28, 146-150 (2005)
2. Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., et al.: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20, 716-731 (1993)
3. Kwekkeboom, D., Krenning, E. P. and de Jong, M.: Peptide receptor imaging and therapy. J Nucl Med 41, 1704-1713 (2000)
4. Valkema, R., De Jong, M., Bakker, W. H., et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32, 110-122 (2002)
5. Bodei, L., Cremonesi, M., Zoboli, S., et al.: Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 30, 207-216 (2003)
6. Valkema, R., Pauwels, S., Kvols, L. K., et al.: Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36, 147-156 (2006)
7. Otte, A., Herrmann, R., Heppeler, A., et al.: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 26, 1439-1447 (1999)
8. Waldherr, C., Pless, M., Maecke, H. R., et al.: Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med 43, 610-616 (2002)
9. Chinol, M., Bodei, L., Cremonesi, M., et al.: Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 32, 141-147 (2002)
10. van Essen, M., krenning, E. P., de Jong, M., et al.: Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours Acta Oncology, 46(6):723-34 (2007)
11. Valkema, R., Pauwels, S. A., Kvols, L. K., et al.: Long-term follow-up of renal function after peptide receptor radiation therapy with (90) Y-DOTA (0), Tyr (3)-octreotide and (177) Lu-DOTA (0), Tyr (3)-octreotate. J Nucl Med 46(Suppl 1), 83S-91S (2005)
12. Reubi, J. C., Schar, J. C., Waser, B., et al.: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27, 273-282 (2000)
13. de Jong, M., Breeman, W. A., Bakker, W. H., et al.: Comparison of (111) In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58, 437-441 (1998)
14. Esser, J. P., Krenning, E. P., Teunissen, J. J., et al.: Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 33, 1346-1351 (2006)
15. Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., et al.: [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28, 1319-1325 (2001)
16. O'Donoghue, J. A., Bardies, M. and Wheldon, T. E.: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36, 1902-1909 (1995)
17. de Jong, M., Breeman, W. A., Valkema, R., et al.: Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46(Suppl 1), 13S-17S (2005)
18. Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., et al.: Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23, 2754-2762 (2005)
19. Teunissen, J. J., Kwekkeboom, D. J. and Krenning, E. P.: Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol 22, 2724-2729 (2004)
20. Zhang, H., Chen, J., Waldherr, C., et al.: Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64, 6707-6715 (2004)
21. Breeman, W. A., Hofland, L. J., de Jong, M., et al.: Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 81, 658-665 (1999)
22. Ginj, M., Zhang, H., Waser, B., et al.: Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103, 16436-16441 (2006)
23. Cescato, R., Maina, T., Nock, B., et al.: Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49, 318-326 (2008)
24. 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptorexpressing tumors. J Nucl Med 44, 708-716 (2003)
25. 99mTc-tricine-HYNIC-D-Phe1- Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med 27, 628-637 (2000)
26. 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid. Exp Clin Endocrinol Diabetes 115, 47-49 (2007)
27. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Eur J Nucl Med Mol Imaging 33, 1123-1133 (2006)
28. 99m) Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid. Nucl Med Rev Cent East Eur 8, 155-156 (2005)
29. 99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm 19, 73-79 (2004)
30. 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumorbearing mice. J Pept Sci 12, 124-131 (2006)
31. 99mTc-Demotate 1: first data in tumour patientsresults of a pilot/phase I study. Eur J Nucl Med Mol Imaging 30, 1211-1219 (2003)
32. Breeman, W. A., de Jong, M., de Blois, E., et al.: Radiolabelling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging 32, 478-485 (2005)
33. Antunes, P., Ginj, M., Zhang, H., et al.: Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34, 982-993 (2007)
34. Kowalski, J., Henze, M., Schuhmacher, J., et al.: Evaluation of positron emission tomography imaging using [68 Ga]-DOTA-D Phe (1)-Tyr (3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5, 42-48 (2003)
35. Gabriel, M., Decristoforo, C., Kendler, D., et al.: 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48, 508-518 (2007)
36. Kulaksiz, H., Eissele, R., Rossler, D., et al.: Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50, 52-60 (2002)
37. Reubi, J. C., Waser, B., Schaer, J. C., et al.: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28, 836-846 (2001)
38. Ginj, M., Schmitt, J. S., Chen, J., et al.: Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 13, 1081-1090 (2006)
39. Wild, D., Macke, H. R., Waser, B., et al.: 68 Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32, 724 (2005)
40. Pettinato, C., Sarnelli, A., Di Donna, M., et al.: (68) Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 35, 72-79 (2008)
41. Wehrmann, C., Senftleben, S., Zachert, C., et al.: Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22, 406-416 (2007)
42. Reubi, J. C., Wenger, S., Schmuckli-Maurer, J., et al.: Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125) I-[D-TYR (6), beta-ALA (11), PHE (13), NLE (14)] bombesin (6-14). Clin Cancer Res 8, 1139-1146 (2002)
43. Jemal, A., Siegel, R., Ward, E., et al.: Cancer statistics, 2007. CA Cancer J Clin 57, 43-66 (2007)
44. Breeman, W. A., de Jong, M., Bernard, B., et al.: Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats. Anticancer Res 18, 83-89 (1998)
45. 99m) Tc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30, 247-258 (2003)
46. 99mTc: a preclinical study. J Med Chem 48, 100-110 (2005)
47. 99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27, 1694-1699 (2000)
48. van Bokhoven, A., Varella-Garcia, M., Korch, C., et al.: Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205-225 (2003)
49. Hoffman, T. J., Gali, H., Smith, C. J., et al.: Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44, 823-831. (2003)
50. Breeman, W. A., de Jong, M., Erion, J. L., et al.: Preclinical comparison of (111) In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43, 1650-1656 (2002)
51. 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours. Nucl Med Commun 27, 371-376 (2006)
52. 99m) Tc] (CO) (3) bombesin analogues. Nucl Med Biol 34, 17-28 (2007)
53. Reubi, J. C., Macke, H. R. and Krenning, E. P.: Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46(Suppl 1), 67S-75S (2005)
54. de Visser, M., Bernard, H. F., Erion, J. L., et al.: Novel (111) In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging (2007)
55. Zhang, H., Schuhmacher, J., Waser, B., et al.: DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptorpositive tumours. Eur J Nucl Med 34, 1198-1208 (2007)
56. Yang, Y. S., Zhang, X., Xiong, Z., et al.: Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 33, 371-380 (2006)
57. Smith, C. J., Gali, H., Sieckman, G. L., et al.: Radiochemical investigations of (177) Lu-DOTA-8-Aoc-BBN[7-14]NH (2): an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 30, 101-109 (2003)
58. Rogers, B. E., Bigott, H. M., McCarthy, D. W., et al.: MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Culabeled bombesin analogue. Bioconjug Chem 14, 756-763 (2003)
59. Johnson, C. V., Shelton, T., Smith, C. J., et al.: Evaluation of combined (177) Lu-DOTA-8-AOC-BBN (7-14) NH (2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm 21, 155-166 (2006)
60. Biddlecombe, G. B., Rogers, B. E., Visser, M. D., et al.: Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using (64) Cu- and (86) Y-DOTA-(Pro (1), Tyr (4)) - Bombesin (1-14). Bioconjug Chem 18, 724-730 (2007)
61. Lantry, L. E., Cappelletti, E., Maddalena, M. E., et al.: 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47, 1144-1152 (2006)
62. Van de Wiele, C., Dumont, F., van Belle, S., et al.: Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? Nucl Med Commun 22, 5-15 (2001)
63. Baum, R., Prasad, V., Mutloka, N., et al.: Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: first results. J Nucl Med 48, 79P (2007)
64. de Visser, M., van Weerden, W. M., Melis, M., et al.: Radiolabeled bombesin analogs in preclinical studies. J Nucl Med 48(Suppl 2), 24P (2007)
65. Mancuso, A., Oudard, S. and Sternberg, C. N.: Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit Rev Oncol Hematol 61, 176-185 (2007)
66. Oudard, S., Banu, E., Beuzeboc, P., et al.: Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23, 3343-3351 (2005)
67. de Visser, M., van Weerden, W. M., de Ridder, C. M., et al.: Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 48, 88-93 (2007)
68. Reubi, J. C., Waser, B., Friess, H., et al.: Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42, 546-550 (1998)
69. Kuhar, M. J.: Imaging receptors for drugs in neural tissue. Neuropharmacology 26, 911-916 (1987)
70. Ehlers, R. A., Kim, S., Zhang, Y., et al.: Gut peptide receptor expression in human pancreatic cancers. Ann Surg 231, 838-848 (2000)
71. 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol 33, 505-512 (2006)
72. 99mTc. J Med Chem 49, 4767-4776 (2006)
73. 99mTc-labeled neurotensin analogues with optimized biodistribution properties. J Med Chem 49, 1833-1836 (2006)
74. Garcia-Garayoa, E., Maes, V., Blauenstein, P., et al.: Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors. Nucl Med Biol 33, 495-503 (2006)
75. Garcia-Garayoa, E., Allemann-Tannahill, L., Blauenstein, P., et al.: In vitro and in vivo evaluation of new radiolabeled neurotensin (8-13) analogues with high affinity for NT1 receptors. Nucl Med Biol 28, 75-84 (2001)
76. Lugrin, D., Vecchini, F., Doulut, S., et al.: Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Eur J Pharmacol 205, 191-198 (1991)
77. de Visser, M., Janssen, P. J., Srinivasan, A., et al.: Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging 30, 1134-1139 (2003)
78. Emami, B., Lyman, J., Brown, A., et al.: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21, 109-122 (1991)
79. 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 44, 1649-1654 (2003)
80. Reubi, J. C., Chayvialle, J. A., Franc, B., et al.: Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 64, 567-573 (1991)
81. Kwekkeboom, D. J., Reubi, J. C., Lamberts, S. W., et al.: In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76, 1413-1417 (1993)
82. Reubi, J. C., Schaer, J. C. and Waser, B.: Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57, 1377-1386 (1997)
83. Behr, T. M., Jenner, N., Radetzky, S., et al.: Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25, 424-430 (1998)
84. Reubi, J. C., Waser, B., Schaer, J. C., et al.: Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 25, 481-490 (1998)
85. de Jong, M., Bakker, W. H., Bernard, B. F., et al.: Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 40, 2081-2087 (1999)
86. Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., et al.: Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27, 1312-1317 (2000)
87. Mather, S. J., McKenzie, A. J., Sosabowski, J. K., et al.: Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 48, 615-622 (2007)
88. Behr, T. M., Jenner, N., Behe, M., et al.: Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40, 1029-1044 (1999)
89. 99m) Tc-labeled minigastrin analogs. J Nucl Med 46, 1727-1736 (2005)
90. Gotthardt, M., Behe, M. P., Beuter, D., et al.: Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33, 1273-1279 (2006)
91. Gotthardt, M., Behe, M. P., Grass, J., et al.: Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13, 1203-1211 (2006)
92. Mayo, K. E., Miller, L. J., Bataille, D., et al.: International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55, 167-194 (2003)
93. Reubi, J. C. and Waser, B.: Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30, 781-793 (2003)
94. Korner, M., Stockli, M., Waser, B., et al.: GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting. J Nucl Med 48, 736-743 (2007)
95. Meier, J. J. and Nauck, M. A.: Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 21, 91-117 (2005)
96. Hassan, M., Eskilsson, A., Nilsson, C., et al.: In vivo dynamic distribution of 131I-glucagonlike peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol 26, 413-420 (1999)
97. Gotthardt, M., Fischer, M., Naeher, I., et al.: Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 29, 597-606 (2002)
98. Gotthardt, M., Lalyko, G., van Eerd-Vismale, J., et al.: A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. Regul Pept 137, 162-167 (2006)
99. Wild, D., Behe, M., Wicki, A., et al.: [Lys40 (Ahx-DTPA-111In) NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med 47, 2025-2033 (2006)
100. Wicki, A., Wild, D., Storch, D., et al.: [Lys40 (Ahx-DTPA-111In) NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res 13, 3696-3705 (2007)
101. Brooks, P. C.: Role of integrins in angiogenesis. Eur J Cancer 32 A, 2423-2429 (1996)
102. Plow, E. F., Haas, T. A., Zhang, L., et al.: Ligand binding to integrins. J Biol Chem 275, 21785-21788 (2000)
103. Gurrath, M., Muller, G., Kessler, H., et al.: Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur J Biochem 210, 911-921 (1992)
104. Aumailley, M., Gurrath, M., Muller, G., et al.: Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett 291, 50-54 (1991)
105. van Hagen, P. M., Breeman, W. A., Bernard, H. F., et al.: Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 90, 186-198 (2000)
106. Chen, X., Park, R., Tohme, M., et al.: MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15, 41-49 (2004)
107. Cai, W., Zhang, X., Wu, Y., et al.: A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobe nzamido) ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med 47, 1172-1180 (2006)
108. Haubner, R., Kuhnast, B., Mang, C., et al.: [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15, 61-69 (2004)
109. Beer, A. J., Haubner, R., Sarbia, M., et al.: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha (v) beta3 expression in man. Clin Cancer Res 12, 3942-3949 (2006)
110. Beer, A. J., Haubner, R., Wolf, I., et al.: PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 47, 763-769 (2006)
111. Beer, A. J., Haubner, R., Goebel, M., et al.: Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46, 1333-1341 (2005)
112. Dijkgraaf, I., Kruijtzer, J. A., Liu, S., et al.: Improved targeting of the alpha (v) beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging 34, 267-273 (2007)
113. Dijkgraaf, I., Rijnders, A. Y., Soede, A., et al.: Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1, 3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 5, 935-944 (2007)
114. Dijkgraaf, I., Liu, S., Kruijtzer, J. A., et al.: Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Nucl Med Biol 34, 29-35 (2007)
115. Dijkgraaf, I., Kruijtzer, J. A., Frielink, C., et al.: Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. Int J Cancer 120, 605-610 (2007)
116. Kimura, N., Hayafuji, C., Konagaya, H., et al.: 17 beta-estradiol induces somatostatin (SRIF) inhibition of prolactin release and regulates SRIF receptors in rat anterior pituitary cells. Endocrinology 119, 1028-1036 (1986)
117. Presky, D. H. and Schonbrunn, A.: Somatostatin pretreatment increases the number of somatostatin receptors in GH4C1 pituitary cells and does not reduce cellular responsiveness to somatostatin. J Biol Chem 263, 714-721 (1988)
118. Kimura, N., Hayafuji, C. and Kimura, N.: Characterization of 17-beta-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary. J Biol Chem 264, 7033-7040 (1989)
119. Slama, A., Videau, C., Kordon, C., et al.: Estradiol regulation of somatostatin receptors in the arcuate nucleus of the female rat. Neuroendocrinology 56, 240-245 (1992)
120. Vidal, C., Rauly, I., Zeggari, M., et al.: Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol 46, 97-104 (1994)
121. Visser-Wisselaar, H. A., Van Uffelen, C. J., Van Koetsveld, P. M., et al.: 17-beta-estradioldependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology 138, 1180-1189 (1997)
122. Froidevaux, S., Hintermann, E., Torok, M., et al.: Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment. Cancer Res 59, 3652-3657 (1999)
123. Viguerie, N., Esteve, J. P., Susini, C., et al.: Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem Biophys Res Commun 147, 942-948 (1987)
124. Gunn, S. H., Schwimer, J. E., Cox, M., et al.: In vitro modeling of the clinical interactions between octreotide and 111In-pentetreotide: is there evidence of somatostatin receptor downregulation? J Nucl Med 47, 354-359 (2006)
125. Behe, M., Püsken, M., Henzel, M., et al.: Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med Mol Imaging 30, S218 (2003)
126. Behe, M., Koller, S., Püsken, M., et al.: Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 31, S237-S238 (2004)
127. Oddstig, J., Bernhardt, P., Nilsson, O., et al.: Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol 33, 841-846 (2006)
128. Capello, A., Krenning, E., Bernard, B., et al.: 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 32, 1288-1295 (2005)
129. Melis, M., Forrer, F., Capello, A., et al.: Up-regulation of somatostatin receptor density on rat CA20948 tumours escaped from low dose [177Lu-DOTA0, Tyr3]octreotate therapy. Q J Nucl Med Mol Imaging 51, 324-33 (2007)
130. Seth, P.: Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther 4, 512-517 (2005)
131. 99mTc-labeled peptides of somatostatin receptors upregulated by adenovirus infection. Society of Nuclear Medicine, 47th Annual meeting, 246-251 (2000)
132. Zinn, K. R., Chaudhuri, T. R., Buchsbaum, D. J., et al.: Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging. Nucl Med Biol 28, 135-144 (2001)
133. Hemminki, A., Belousova, N., Zinn, K. R., et al.: An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 4, 223-231 (2001)
134. Zinn, K. R., Chaudhuri, T. R., Krasnykh, V. N., et al.: Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice. Radiology 223, 417-425 (2002)
135. Verwijnen, S. M., ter Horst, M., Sillevis Smith, P. A. E., et al.: Molecular imaging following adenoviral gene transfer visualizes sst2 and HSV1-tk expression (submitted) (2007)
136. Rogers, B. E., Zinn, K. R., Lin, C. Y., et al.: Targeted radiotherapy with [(90) Y]-SMT 487 in mice bearing human nonsmall cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer 94, 1298-1305 (2002)
137. Rogers, B. E., Parry, J. J., Andrews, R., et al.: MicroPET imaging of gene transfer with a somatostatin receptor-based reporter gene and (94 m) Tc-Demotate 1. J Nucl Med 46, 1889-1897 (2005)
138. Gotthardt, M., Librizzi, D., Wolf, D., et al.: Increased therapeutic efficacy through combination of Lu-177-DOTATOC and chemotheray in neuroendocrine tumours in vivo. Eur J Nucl Med Mol Imaging 33, S115 (2006)
139. Kong, G., Lau, E., Ramdave, S., et al.: High-dose In-111 octreotide therapy in combination with radiosensitizing 5-FU chemotherapy for treatment of SSR-expressing neuroendocrine tumors. J Nucl Med 46, 151P-152P (2005)
140. Wild, D., Wicki, A. and Christofori, G.: Combination therapy with [(lys40 (Ahx-[111In-DTPA])]-Exendin-4 and VEGF-receptor tyrosine kinase inhibitor PTK in a glucagon-like-peptide-1 receptor-positive transgenic mouse tumor model. J Nucl Med 48(Suppl 2), 83P (2007)
141. Fueger, B. J., Hamilton, G., Raderer, M., et al.: Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 42, 1856-1862 (2001)
142. de Jong, M., Breeman, W. A., Bernard, B. F., et al.: [177Lu-DOTA (0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92, 628-633 (2001)
143. de Jong, M., Breeman, W. A., Bernard, B. F., et al.: Tumor response after [(90) Y-DOTA (0), T yr (3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42, 1841-1846 (2001)
144. Schally, A. V. and Nagy, A.: Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 141, 1-14 (1999)
145. Nagy, A. and Schally, A. V.: Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des 11, 1167-1180 (2005)
146. Hofland, L. J., Capello, A., Krenning, E. P., et al.: Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. J Nucl Med 46(Suppl 1), 191S-198S (2005)
147. Keller, G., Schally, A. V., Nagy, A., et al.: Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multidrug resistance proteins. Int J Oncol 28, 1507-1513 (2006)
148. Engel, J. B., Schally, A. V., Halmos, G., et al.: Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 104, 1312-1321 (2005)
149. Buchholz, S., Keller, G., Schally, A. V., et al.: Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA 103, 10403-10407 (2006)
150. Kanashiro, C. A., Schally, A. V., Nagy, A., et al.: Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. Int J Oncol 27, 169-174 (2005)
151. Kiaris, H., Schally, A. V., Nagy, A., et al.: Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238. Clin Cancer Res 6, 709-717 (2000)
152. Szereday, Z., Schally, A. V., Nagy, A., et al.: Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215. Br J Cancer 86, 1322-1327 (2002)
153. Moody, T. W., Fuselier, J., Coy, D. H., et al.: Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides 26, 1560-1566 (2005)
154. Sun, L. C., Luo, J., Mackey, L. V., et al.: A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 246, 157-166 (2007)
155. Moody, T. W., Sun, L. C., Mantey, S. A., et al.: In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 318, 1265-1272 (2006)
156. Sun, L. C., Luo, J., Mackey, V. L., et al.: Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs 18, 341-348 (2007)
157. Bernard, B., Capello, A., van Hagen, M., et al.: Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 19, 173-180 (2004)
158. Capello, A., Krenning, E. P., Bernard, B. F., et al.: Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. J Nucl Med 45, 1716-1720 (2004)
159. Capello, A., Krenning, E. P., Bernard, B. F., et al.: Anticancer activity of targeted proapoptotic peptides. J Nucl Med 47, 122-129 (2006)
160. Buckley, C. D., Pilling, D., Henriquez, N. V., et al.: RGD peptides induce apoptosis by direct caspase-3 activation. Nature 397, 534-539 (1999)
161. Lambert, B., Cybulla, M., Weiner, S. M., et al.: Renal toxicity after radionuclide therapy. Radiat Res 161, 607-611 (2004)
162. Kwekkeboom, D. J., Mueller-Brand, J., Paganelli, G., et al.: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1), 62S-66S (2005)
163. Melis, M., Krenning, E. P., Bernard, B. F., et al.: Localisation and
164. De Jong, M., Valkema, R., Van Gameren, A., et al.: Inhomogeneous Localization of Radioactivity in the Human Kidney After Injection of [(111) In-DTPA]Octreotide. J Nucl Med 45, 1168-1171 (2004)
165. de Jong, M., Barone, R., Krenning, E., et al.: Megalin is essential for renal proximal tubule reabsorption of (111) In-DTPA-octreotide. J Nucl Med 46, 1696-1700 (2005)
166. Rolleman, E. J., Kooij, P. P., de Herder, W. W., et al.: Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med 34, 1854-1860 (2007)
167. Rolleman, E. J., Valkema, R., de Jong, M., et al.: Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 30, 9-15 (2003)
168. Verwijnen, S. M., Krenning, E. P., Valkema, R., et al.: Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide. J Nucl Med 46, 2057-2060 (2005)
169. van Eerd, J. E., Vegt, E., Wetzels, J. F., et al.: Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 47, 528-533 (2006)
170. Vegt, E., Wetzels, J. F., Russel, F. G., et al.: Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47, 432-436 (2006)
171. Rolleman, E. J., Krenning, E. P., Van Gameren, A., et al.: Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 45, 709-713 (2004)
172. Rolleman, E. J., Forrer, F., Bernard, B., et al.: Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [(177) Lu-DOTA (0), Tyr (3)]octreotate. Eur J Nucl Med Mol Imaging 34, 763-771 (2007)